



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C12N 15/54, 15/62, 15/10, 15/63, 9/10	A1	(11) International Publication Number: WO 94/12646 (43) International Publication Date: 9 June 1994 (09.06.94)
<p>(21) International Application Number: PCT/EP93/03194</p> <p>(22) International Filing Date: 15 November 1993 (15.11.93)</p> <p>(30) Priority Data: 92810924.8 27 November 1992 (27.11.92) EP</p> <p>(34) Countries for which the regional or international application was filed: DE et al.</p> <p>(71) Applicant (for all designated States except US): CIBA-GEIGY AG [CH/CH]; Klybeckstrasse 141, CH-4002 Basle (CH).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BERGER, Eric, G. [CH/CH]; Zum Müliweiher 4, CH-8165 Schöflisdorf (CH). WATZELE, Manfred [DE/DE]; Ringstrasse 2, D-82362 Weilheim (DE). IWANOW, Svetoslav, X. [BG/BG]; ul. "Ivan Assen 2" Nr. 37, Sofia 1504 (BG).</p> <p>(74) Common Representative: CIBA-GEIGY AG; Patentabteilung, Klybeckstrasse 141, CH-4002 Basel (CH).</p>	<p>(81) Designated States: AU, CA, FI, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p><b>BEST AVAILABLE COPY</b></p>	
<p>(54) Title: PROTEINS HAVING GLYCOSYLTRANSFERASE ACTIVITY</p> <p>(57) Abstract</p> <p>The invention concerns proteins having glycosyltransferase activity, recombinant DNA molecules encoding proteins having glycosyltransferase activity, hybrid vectors comprising such recombinant DNA molecules, transformed hosts suitable for the multiplication and/or expression of the recombinant DNA molecules, and processes for the preparation of the proteins, DNA molecules and hosts.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

Proteins having glycosyltransferase activity

The invention relates to proteins having glycosyltransferase activity and to a recombinant process for the production of proteins having glycosyltransferase activity.

Glycosyltransferases transfer sugar residues from an activated donor substrate, usually a nucleotide sugar, to a specific acceptor sugar thus forming a glycosidic linkage. Based on the type of sugar transferred, these enzymes are grouped into families, e.g. galactosyltransferases, sialyltransferases and fucosyltransferases. Being resident membrane proteins primarily located in the Golgi apparatus, the glycosyltransferases share a common domain structure consisting of a short amino-terminal cytoplasmic tail, a signal-anchor domain, and an extended stem region which is followed by a large carboxy-terminal catalytic domain. The signal-anchor or membrane domain acts as both uncleavable signal peptide and as membrane spanning region and orients the catalytic domain of the glycosyltransferase within the lumen of the Golgi apparatus. The luminal stem or spacer region is supposed to serve as a flexible tether, allowing the catalytic domain to glycosylate carbohydrate groups of membrane-bound and soluble proteins of the secretory pathway enroute through the Golgi apparatus. Furthermore, the stem portion was discovered to function as retention signal to keep the enzyme bound to the Golgi membrane (PCT Application No. 91/06635). Soluble forms of glycosyltransferases are found in milk, serum and other body fluids. These soluble glycosyltransferases are supposed to result from proteolytic release from the corresponding membrane-bound forms of the enzymes by endogenous proteases.

Glycosyltransferases are valuable tools for the synthesis or modification of glycoproteins, glycolipids and oligosaccharides. Enzymatic synthesis of carbohydrate structures has the advantage of high stereo- and regioselectivity. In contrast to chemical methods the time-consuming introduction of protective groups is superfluous. However, enzymatic synthesis of carbohydrate structures has been a problem because glycosyltransferases are not readily available. Therefore, production using recombinant DNA technology has been worked on. For example, galactosyltransferases have been expressed in *E. coli* (PCT 90/07000) and Chinese hamster ovary (CHO) cells (Smith, D.F. et al. (1990) *J. Biol. Chem.* 265, 6225-34), sialyltransferases have been expressed in CHO cells (Lee, E.U. (1990) *Diss. Abstr. Int.B.50*, 3453-4) and COS-1 cells (Paulson, J.C. et al. (1988) *J. Cell.*

- 2 -

Biol. 107, 10A), and fucosyltransferases have been produced in COS-1 cells (Goelz, S.E. et al. (1990) Cell 63, 1349-1356; Larsen R.D. et al. (1990) Proc. Natl. Acad. Sci. USA 87, 6674-6678) and CHO cells (Potvin, B. (1990) J. Biol. Chem. 265, 1615-1622). Recently, Paulson et al. have disclosed a method for producing soluble glycosyltransferases (U.S. Patent No. 5,032,519). However, there still is a need for proteins having favorable glycosylating properties and for advantageous methods for producing such proteins.

It is an object of the present invention to provide novel proteins having glycosyltransferase activity, recombinant DNA molecules encoding proteins having glycosyltransferase activity, hybrid vectors comprising such recombinant DNA molecules, transformed hosts suitable for the multiplication and/or expression of the recombinant DNA molecules, and processes for the preparation of the proteins, DNA molecules and hosts.

The present invention concerns a protein having glycosyltransferase activity and comprising identical or different catalytically active domains of glycosyltransferases, e.g. hybrid proteins.

Preferred is a protein of the invention which comprises two identical or two different catalytically active domains of glycosyltransferases.

Particularly preferred is such a protein exhibiting two different glycosyltransferase activities, i.e. a protein capable of transferring two different sugar residues.

Besides the catalytically active domains a protein of the invention may comprise additional amino acid sequences, particularly amino acid sequences of the respective glycosyltransferases.

The invention also concerns a hybrid polypeptide chain, i.e. a hybrid protein, comprising a membrane-bound or soluble glycosyltransferase linked to a soluble glycosyltransferase. For example, such a hybrid protein comprises a membrane-bound glycosyltransferase linked to a soluble glycosyltransferase in N-to C-terminal order.

A glycosyltransferase is a protein exhibiting glycosyltransferase activity, i.e. transferring a particular sugar residue from a donor molecule to an acceptor molecule. Examples are N-acetylglucosaminyltransferases, N-acetylgalactosaminyltransferases, mannosyltransferases, fucosyltransferases, galactosyltransferases and sialyltransferases.

- 3 -

Preferably, the glycosyltransferase is of mammalian, e.g. bovine, murine, rat or, particularly, human origin.

Preferred are hybrid proteins exhibiting galactosyl- and sialyltransferase activity.

A membrane-bound glycosyltransferase is an enzyme which cannot be secreted by the cell it is produced by, e.g. a full-length enzyme. Examples of membrane-bound glycosyltransferases are the following galactosyltransferases: UDP-Galactose:  $\beta$ -galactoside  $\alpha$ (1-3)-galactosyltransferase (EC 2.4.1.151) which uses galactose as acceptor substrate forming an  $\alpha$ (1-3)-linkage and UDP-Galactose:  $\beta$ -N-acetylglucosamine  $\beta$ (1-4)-galactosyltransferase (EC 2.4.1.22) which transfers galactose to N-acetylglucosamine (GlcNAc) forming a  $\beta$ (1-4)-linkage. In the presence of  $\alpha$ -lactalbumin, said  $\beta$ (1-4)-galactosyltransferase also accepts glucose as an acceptor substrate, thus catalysing the synthesis of lactose. An example of a membrane-bound sialyltransferase is the CMP-NeuAc:  $\beta$ -galactoside  $\alpha$ (2-6)-sialyltransferase (EC 2.4.99.1) which forms the NeuAc- $\alpha$ (2-6)Gal- $\beta$ (1-4)GlcNAc-sequence common to many N-linked carbohydrate groups.

A soluble glycosyltransferase is secreted by the host cell and is derivable from an N-terminally truncated full-length (i.e. a membrane-bound) glycosyltransferase naturally located in the Golgi apparatus. Such a soluble glycosyltransferase differs from the corresponding full-length enzyme by lack of the cytoplasmic tail, the signal anchor and, optionally, part or whole of the stem region. An example of soluble glycosyltransferases are galactosyltransferases differing from the protein with the amino acid sequence depicted in SEQ ID NO. 1 in that they lack an  $\text{NH}_2$ -terminal peptide comprising at least 41 amino acids. A soluble sialyltransferase is e.g. a sialyltransferase missing an  $\text{NH}_2$ -terminal peptide consisting of 26 to 61 amino acids as compared to the full length form depicted in SEQ ID No. 3.

As used hereinbefore and hereinafter the term "glycosyltransferase" is intended to include variants with the provision that these variants are enzymatically active. Preferred are variants of human origin.

For example, a variant is a naturally occurring variant of a glycosyltransferase found within a particular species, e.g. a variant of a galactosyltransferase which differs from the enzyme having the amino acid sequence with the SEQ ID NO. 1 in that it lacks serine in

- 4 -

position 11 and has the amino acids valine and tyrosine instead of alanine and leucine in positions 31 and 32, respectively. Such a variant may be encoded by a related gene of the same gene family or by an allelic variant of a particular gene. The term "variant" also embraces a modified glycosyltransferase, e.g. a glycosyltransferase produced from a DNA which has been subjected to in vitro mutagenesis, with the provision that the protein encoded by said DNA has the enzymatic activity of the authentic glycosyltransferase. Such modifications may consist in an addition, exchange and/or deletion of one or more amino acids, the latter resulting in shortened variants. An example of a shortened membrane-bound, catalytically active variant is the galactosyltransferase designated GT<sub>(1-396)</sub> consisting of amino acids 1 to 396 of the amino acid sequence depicted in SEQ ID No. 1.

Preferred hybrid proteins comprise a membrane-bound or soluble glycosyltransferase linked to a soluble glycosyltransferase molecule, or a variant thereof, via a suitable linker consisting of genetically encoded amino acids. A suitable linker is a molecule which does not impair the favorable properties of the hybrid protein of the invention. The linker connects the C-terminal amino acid of one glycosyltransferase molecule with the N-terminal amino acid of the another glycosyltransferase molecule. For example, the linker is a peptide consisting of about 1 to about 20, e.g. of about 8 amino acids. In a preferred embodiment the linker, also referred to as adaptor, does not contain the amino acid cysteine. Particularly preferred is a peptide linker having the sequence Arg-Ala-Arg-Ile-Arg-Arg-Pro-Ala or Arg-Ala-Gly-Ile-Arg-Arg-Pro-Ala.

Preferred is a hybrid protein consisting of a galactosyltransferase linked to a sialyltransferase via a suitable peptide linker.

Particularly preferred is a hybrid protein consisting of a membrane-bound galactosyltransferase the C-terminal amino acid of which is linked to the N-terminal amino acid of a soluble sialyltransferase via a suitable peptide linker, e.g. a hybrid protein having the amino acid sequence set forth in SEQ ID NO. 6 or in SEQ ID NO. 8.

The hybrid protein according to the invention can be prepared by recombinant DNA techniques comprising culturing a suitable transformed yeast strain under conditions which allow the expression of the DNA encoding said hybrid protein. Subsequently, the enzymatic activity may be recovered.

- 5 -

In a preferred embodiment, the desired compounds are manufactured in a process comprising

- a) providing an expression vector comprising an expression cassette containing a DNA sequence coding for a hybrid protein,
- b) transferring the expression vector into a suitable yeast strain,
- c) culturing the transformed yeast strain under conditions which allow expression of the hybrid protein, and
- d) recovering the enzymatic activity.

The steps involved in the preparation of the hybrid proteins by means of recombinant techniques will be discussed in more detail hereinbelow.

The invention further relates to a recombinant DNA molecule encoding a hybrid protein of the invention. Preferred are DNA molecules coding for the preferred hybrid proteins.

The nucleotide sequence encoding a particular glycosyltransferase is known from the literature or can be deduced from the amino acid sequence of the protein according to conventional rules. Starting from the nucleotide sequences encoding the desired glycosyltransferase activities, a DNA molecule encoding the desired hybrid protein can be deduced and constructed according to methods well known in the art including, but not limited to, the use of polymerase chain reaction (PCR) technology, DNA restriction enzymes, synthetic oligonucleotides, DNA ligases and DNA amplification techniques. Alternatively, the nucleotide sequence encoding the hybrid protein of the invention may be synthesized by chemical methods known in the art or by combining chemical with recombinant methods.

The DNA coding for a particular glycosyltransferase may be obtained from cell sources by conventional methods, e.g. by making use of cDNA technology, from vectors in the art or by chemical synthesis of the DNA.

More specifically, DNA encoding a membrane-bound glycosyltransferase can be prepared by methods known in the art and includes genomic DNA, e.g. DNA isolated from a

- 6 -

mammalian genomic DNA library, e.g. from rat, murine, bovine or human cells. If necessary, the introns occurring in genomic DNA encoding the enzyme are deleted. Furthermore, DNA encoding a membrane-bound glycosyltransferase comprises cDNA which can be isolated from a mammalian cDNA library or produced from the corresponding mRNA. The cDNA library may be derived from cells from different tissues, e.g. placenta cells or liver cells. The preparation of cDNA via the mRNA route is achieved using conventional methods such as the polymerase chain reaction (PCR).

A DNA encoding a soluble glycosyltransferase is obtainable from a naturally occurring genomic DNA or a cDNA according to methods known in the art. For example, the partial DNA coding for a soluble form of a glycosyltransferase may be excised from the full-length DNA coding for the corresponding membrane-bound glycosyltransferase by using restriction enzymes. The availability of an appropriate restriction site is advantageous therefor.

Furthermore, DNA encoding a glycosyltransferase can be enzymatically or chemically synthesized.

A variant of a glycosyltransferase having enzymatic activity and an amino acid sequence in which one or more amino acids are deleted (DNA fragments) and/or exchanged with one or more other amino acids, is encoded by a mutant DNA. Furthermore, a mutant DNA is intended to include a silent mutant wherein one or more nucleotides are replaced with other nucleotides, the new codons coding for the same amino acid(s). Such a mutant sequence is also a degenerated DNA sequence. Degenerated DNA sequences are degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerated DNA sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host to obtain optimal expression of a glycosyltransferase. Preferably, such DNA sequences have the yeast preferred codon usage.

A mutant DNA is obtainable by in vitro mutation of a cDNA or of a naturally occurring genomic DNA according to methods known in the art.

The invention also concerns hybrid vectors comprising a DNA sequence encoding a hybrid protein of the invention. The hybrid vectors of the invention provide for replication



- 7 -

and, optionally, expression of the DNA encoding a hybrid protein of the invention. A hybrid vector of the invention comprises a DNA sequence encoding a hybrid protein of the invention linked with an origin of replication allowing the replication of the vector in the host cell, or a functionally equivalent sequence. A vector suitable for the expression of the hybrid protein of the invention (an expression vector) comprises a DNA sequence encoding said hybrid protein operably linked with expression control sequences, e.g. promoters, which ensure the effective expression of the hybrid proteins in yeast, and an origin of replication allowing the replication of the vector in the host cell, or a functionally equivalent sequence.

Vectors suitable for replication and expression in yeast contain a yeast replication origin. Hybrid vectors that contain a yeast replication origin, for example the chromosomal autonomously replicating segment (ars), are retained extrachromosomally within the yeast cell after transformation and are replicated autonomously during mitosis. Also, hybrid vectors that contain sequences homologous to the yeast 2 $\mu$  plasmid DNA can be used. Such hybrid vectors are integrated by recombination in 2 $\mu$  plasmids already present within the cell, or replicate autonomously.

Preferably, the hybrid vectors according to the invention include one or more, especially one or two, selective genetic markers for yeast and such a marker and an origin of replication for a bacterial host, especially Escherichia coli.

As to the selective gene markers for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene. Suitable markers for yeast are, for example, those expressing antibiotic resistance or, in the case of auxotrophic yeast mutants, genes which complement host lesions. Corresponding genes confer, for example, resistance to the antibiotics G418, hygromycin or bleomycin or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2 or TRP1 gene.

As the amplification of the hybrid vectors is conveniently done in E. coli, an E. coli genetic marker and an E. coli replication origin are included advantageously. These can be obtained from E. coli plasmids, such as pBR322 or a pUC plasmid, for example pUC18 or pUC19, which contain both E. coli replication origin and E. coli genetic marker conferring resistance to antibiotics, such as ampicillin.

- 8 -

An expression vector according to the invention comprises an expression cassette comprising a yeast promoter and a DNA sequence coding for hybrid protein of the invention, which DNA sequence is controlled by said promoter.

In a first embodiment, an expression vector according to the invention comprises an expression cassette comprising a yeast promoter, a DNA sequence coding for a hybrid protein, which DNA sequence is controlled by said promoter, and a DNA sequence containing yeast transcription termination signals.

In a second embodiment, the an expression vector according to the invention comprises an expression cassette comprising a yeast promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding a hybrid protein, and a DNA sequence containing yeast transcription termination signals.

The yeast promoter may be a regulated or a constitutive promoter preferably derived from a highly expressed yeast gene, especially a Saccharomyces cerevisiae gene. Thus, the promoter of the TRP1 gene, the ADHI or ADHII gene, the acid phosphatase (PH05) gene, a promoter of the yeast mating pheromone genes coding for the  $\alpha$ - or  $\alpha$ -factor or a promoter derived from a gene encoding a glycolytic enzyme such as the promoter of the enolase, glyceraldehyde-3-phosphate dehydrogenase (GAP), 3-phosphoglycerate kinase (PGK), hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase or glucokinase genes can be used. Furthermore, it is possible to use hybrid promoters comprising upstream activation sequences (UAS) of one yeast gene and downstream promoter elements including a functional TATA box of another yeast gene, for example a hybrid promoter including the UAS(s) of the yeast PH05 gene and downstream promoter elements including a functional TATA box of the yeast GAP gene (PH05 - GAP hybrid promoter). Preferred is the PH05 promoter, e.g. a constitutive PH05 promoter such as a shortened acid phosphatase PH05 promoter devoid of the upstream regulatory elements (UAS). Particularly preferred is the PH05 (-173) promoter element starting at nucleotide -173 and ending at nucleotide -9 of the PH05 gene.

The DNA sequence encoding a signal peptide ("signal sequence") is preferably derived from a yeast gene coding for a polypeptide which is ordinarily secreted. Other signal sequences of heterologous proteins, which are ordinarily secreted can also be chosen.

- 9 -

Yeast signal sequences are, for example, the signal and prepro sequences of the yeast invertase,  $\alpha$ -factor, pheromone peptidase (KEX1), "killer toxin" and repressible acid phosphatase (PH05) genes and the glucoamylase signal sequence from *Aspergillus awamori*. Alternatively, fused signal sequences may be constructed by ligating part of the signal sequence (if present) of the gene naturally linked to the promoter used (for example PH05), with part of the signal sequence of another heterologous protein. Those combinations are favoured which allow a precise cleavage between the signal sequence and the glycosyltransferase amino acid sequence. Additional sequences, such as pro- or spacer-sequences which may or may not carry specific processing signals can also be included in the constructions to facilitate accurate processing of precursor molecules. Alternatively, fused proteins can be generated containing internal processing signals which allow proper maturation *in vivo* or *in vitro*. For example, the processing signals contain Lys-Arg, which is recognized by a yeast endopeptidase located in the Golgi membranes.

A DNA sequence containing yeast transcription termination signals is preferably the 3' flanking sequence of a yeast gene which contains proper signals for transcription termination and polyadenylation. Suitable 3' flanking sequences are for example those of the yeast gene naturally linked to the promoter used. The preferred flanking sequence is that of the yeast PH05 gene.

If a hybrid protein comprising a membrane-bound glycosyltransferase is expressed in yeast, the preferred yeast hybrid vector comprises an expression cassette comprising a yeast promoter, a DNA sequence encoding said hybrid protein, which DNA sequence is controlled by said promoter, and a DNA sequence containing yeast transcription termination signals. If the DNA encodes a hybrid protein comprising a membrane-bound glycosyltransferase there is no need for an additional signal sequence.

In case the hybrid protein to be expressed comprises two soluble glycosyltransferases, the preferred yeast hybrid vector comprises an expression cassette comprising a yeast promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding hybrid protein and a DNA sequence containing yeast transcription termination signals.

The hybrid vectors according to the invention are prepared by methods known in the art, for example by linking the expression cassette comprising a yeast promoter and a DNA sequence coding for a glycosyltransferase, or a variant thereof, which DNA sequence is

- 10 -

controlled by said promoter, or the several constituents of the expression cassette, and the DNA fragments containing selective genetic markers for yeast and for a bacterial host and origins of replication for yeast and for a bacterial host in the predetermined order, i.e. in a functional array.

The hybrid vectors of the invention are used for the transformation of the yeast strains described below.

The invention concerns furthermore a yeast strain which has been transformed with a hybrid vector of the invention.

Suitable yeast host organisms are strains of the genus Saccharomyces, especially strains of Saccharomyces cerevisiae. Said yeast strains include strains which, optionally, have been cured of endogenous two-micron plasmids and/or which optionally lack yeast peptidase activity(ies), e.g. peptidase ysc $\alpha$ , yscA, yscB, yscY and/or yscS activity.

The yeast strains of the invention are used for the preparation of a hybrid protein of the invention.

The transformation of yeast with the hybrid vectors according to the invention is accomplished by methods known in the art, for example according to the methods described by Hinnen et al. (Proc. Natl. Acad. Sci. USA (1978) 75, 1929) and Ito et al. (J. Bact. (1983) 153, 163-168).

The transformed yeast strains are cultured using methods known in the art.

Thus, the transformed yeast strains according to the invention are cultured in a liquid medium containing assimilable sources of carbon, nitrogen and inorganic salts.

Various carbon sources are usable. Examples of preferred carbon sources are assimilable carbohydrates, such as glucose, maltose, mannitol, fructose or lactose, or an acetate such as sodium acetate, which can be used either alone or in suitable mixtures. Suitable nitrogen sources include, for example, amino acids, such as casamino acids, peptides and proteins and their degradation products, such as tryptone, peptone or meat extracts, furthermore yeast extract, malt extract, corn steep liquor, as well as ammonium salts, such as ammonium chloride, sulphate or nitrate which can be used either alone or in suitable

- 11 -

mixtures. Inorganic salts which may be used include, for example, sulphates, chlorides, phosphates and carbonates of sodium, potassium, magnesium and calcium. Additionally, the nutrient medium may also contain growth promoting substances. Substances which promote growth include, for example, trace elements, such as iron, zinc, manganese and the like, or individual amino acids.

Due to the incompatibility between the endogenous two-micron DNA and hybrid vectors carrying its replicon, yeast cells transformed with such hybrid vectors tend to lose the latter. Such yeast cells have to be grown under selective conditions, i.e. conditions which require the expression of a plasmid-encoded gene for growth. Most selective markers currently in use and present in the hybrid vectors according to the invention (infra) are genes coding for enzymes of amino acid or purine biosynthesis. This makes it necessary to use synthetic minimal media deficient in the corresponding amino acid or purine base. However, genes conferring resistance to an appropriate biocide may be used as well [e.g. a gene conferring resistance to the amino-glycoside G418]. Yeast cells transformed with vectors containing antibiotic resistance genes are grown in complex media containing the corresponding antibiotic whereby faster growth rates and higher cell densities are reached.

Hybrid vectors comprising the complete two-micron DNA (including a functional origin of replication) are stably maintained within strains of Saccharomyces cerevisiae which are devoid of endogenous two-micron plasmids (so-called  $cir^0$  strains) so that the cultivation can be carried out under non-selective growth conditions, i.e. in a complex medium.

Yeast cells containing hybrid plasmids with a constitutive promoter express the DNA encoding a glycosyltransferase, or a variant thereof, controlled by said promoter without induction. However, if said DNA is under the control of a regulated promoter the composition of the growth medium has to be adapted in order to obtain maximum levels of mRNA transcripts, e.g. when using the PH05 promoter the growth medium must contain a low concentration of inorganic phosphate for derepression of this promoter.

The cultivation is carried out by employing conventional techniques. The culturing conditions, such as temperature, pH of the medium and fermentation time are selected in such a way that maximal levels of the heterologous protein are produced. A chosen yeast strain is e.g. grown under aerobic conditions in submerged culture with shaking or stirring at a temperature of about 25° to 35°C, preferably at about 28°C, at a pH value of from 4 to 7, for example at approximately pH 5, and for at least 1 to 3 days, preferably as long as

- 12 -

satisfactory yields of protein are obtained.

After expression in yeast the hybrid protein of the invention is either accumulated inside the cells or secreted by the cells. In the latter case the hybrid protein is found within the periplasmic space and/or in the culture medium. The enzymatic activity may be recovered e.g. by obtaining the protein from the cell or the culture supernatant by conventional means.

For example, the first step usually consists in separating the cells from the culture fluid by centrifugation. In case the hybrid protein has accumulated within the cells, the enzymatic activity is recovered by cell disruption. Yeast cells can be disrupted in various ways well-known in the art: e.g. by exerting mechanical forces such as shaking with glass beads, by ultrasonic vibration, osmotic shock and/or by enzymatic digestion of the cell wall. If desired, the crude extracts thus obtainable can be directly used for glycosylation. Further enrichment may be achieved for example by differential centrifugation of the cell extracts and/or treatment with a detergent, such as Triton.

In case the hybrid protein is secreted by the yeast cell into the periplasmic space, a simplified isolation protocol can be used: the protein is isolated without cell lysis by enzymatic removal of the cell wall or by chemical agents, e.g. thiol reagents or EDTA, which gives rise to cell wall damages permitting the produced hybrid protein to be released. In case the hybrid protein of the invention is secreted into the culture broth, the enzymatic activity can be isolated directly therefrom.

Methods suitable for the purification of the crude hybrid protein include standard chromatographic procedures such as affinity chromatography, for example with a suitable substrate, antibodies or Concanavalin A, ion exchange chromatography, gel filtration, partition chromatography, HPLC, electrophoresis, precipitation steps such as ammonium sulfate precipitation and other processes, especially those known from the literature.

In order to detect glycosyltransferase activity assays known from the literature can be used. For example, galactosyltransferase activity can be measured by determining the amount of radioactively labelled galactose incorporated into a suitable acceptor molecule such as a glycoprotein or a free sugar residue. Analogously, sialyltransferase activity may be assayed e.g. by the incorporation of sialic acid into a suitable substrate. For a hybrid protein exhibiting two different glycosyltransferase activities the activities may be

- 13 -

assessed individually or together in a 'single pot assay'.

A hybrid protein of the invention is useful e.g. for the synthesis or modification of glycoproteins, oligosaccharides and glycolipids. If the hybrid molecule comprises two different glycosyltransferase activities glycosylation in a one pot reaction is preferred.

The invention especially concerns the hybrid proteins, the recombinant DNA molecules coding therefor, the hybrid vectors and the transformed yeast strains, and the processes for the preparation thereof, as described in the Examples.

In the Examples, the following abbreviations are used: GT = galactosyltransferase (EC 2.4.1.22), PCR = polymerase chain reaction; ST = sialyltransferase (EC 2.4.99.1).

#### Example 1: Cloning of the galactosyltransferase (GT) cDNA from HeLa cells

GT cDNA is isolated from HeLa cells (Watzel, G. and Berger, E.G. (1990)

Nucleic Acids Res. 18, 7174) by the polymerase chain reaction (PCR) method:

##### 1.1 Preparation of poly(A)<sup>+</sup>RNA from HeLa cells

For RNA preparation HeLa cells are grown in monolayer culture on 5 plates (23x23 cm). The rapid and efficient isolation of RNA from cultured cells is performed by extraction with guanidine-HCl as described by Mac Donald, R.J. et al (Meth. Enzymol. (1987) 152, 226-227). Generally, yields are about 0.6 - 1 mg total RNA per plate of confluent cells. Enrichment of poly(A)<sup>+</sup>RNA is achieved by affinity chromatography on oligo(dT)-cellulose according to the method described in the Maniatis manual (Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual (2nd edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA), applying 4 mg of total RNA on a 400 µl column. 3 % of the loaded RNA are recovered as enriched poly(A)<sup>+</sup>RNA which is stored in aliquots precipitated with 3 volumes of ethanol at -70°C until it is used.

##### 1.2 First strand cDNA synthesis for PCR

Poly(A)<sup>+</sup>RNA (mRNA) is reverse-transcribed into DNA by Moloney Murine Leukemia Virus RNase H<sup>-</sup> Reverse Transcriptase (M-MLV H<sup>-</sup> RT) (BRL). In setting up the 20 µl reaction mix, the protocol provided by BRL is followed with minor variations: 1 µg of HeLa cell poly(A)<sup>+</sup>RNA and 500 ng Oligo(dT)<sub>12-18</sub> (Pharmacia) in 11.5 µl sterile H<sub>2</sub>O are

- 14 -

heated to 70°C for 10 min and then quickly chilled on ice. Then 4 µl reaction buffer provided by BRL (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl<sub>2</sub>), 2 µl 0.1 M dithiothreitol, 1 µl mixed dNTP (10 mM each dATP, dCTP, dGTP, dTTP, Pharmacia), 0.5 µl (17.5 U) RNAGuard (RNase Inhibitor of Pharmacia) and 1 µl (200 U)M-MLVH<sup>-</sup> RT are added. The reaction is carried out at 42°C and stopped after 1 h by heating the tube to 95°C for 10 min.

In order to check the efficiency of the reaction an aliquot of the mixture (5 µl) is incubated in the presence of 2 µCi α-<sup>32</sup>P dCTP. By measuring the incorporated dCTP, the amount of cDNA synthesized is calculated. The yield of first strand synthesis is routinely between 5 and 15 %.

### 1.3 Polymerase chain reaction

The oligodeoxynucleotide primers used for PCR are synthesized in vitro by the phosphoramidite method (M.H. Caruthers, in Chemical and Enzymatic Synthesis of Gene Fragments, H.G. Gassen and A. Lang, eds., Verlag Chemie, Weinheim, FRG) on an Applied Biosystems Model 380B synthesizer. They are listed in Table 1.

Table 1: PCR-primers

primer	sequence (5' to 3') <sup>1)</sup>	corresponding to bp in GT cDNA <sup>2)</sup>
Plup (KpnI)	cgcggt <u>ACCCTTCT</u> TAAAGCGGCGGCGGAAGATG	(-26) - 3
P1 (EcoRI)	gccgaattcATGAGGCTTCGGGAGCCGCTCCTGAGCG	1 - 28
P3 (SacI)	CTGGAGCTCGTGGCAAAGCAGAACCC	448 - 473
P2d (EcoRI)	gccgaaTTCAGTCTTTACCTGTACCAAAAGTCCTA	1222-1192
P4 (HindIII)	cccaagctTGAATGATGATGGCCACCTTGTGAGG	546 - 520

1) Capital letters represent sequences from GT, small letters are additional sequences, sites for restriction enzymes are underlined. Codons for 'start' and 'stop' of RNA translation are highlighted in boldface.

2) GT cDNA sequence from human placenta published in GenBank (Accession No. M22921).

Standard PCR-conditions for a 30 µl incubation mixture are: 1 µl of the Reverse Transcriptase reaction (see Example 1.2), containing about 5 ng first strand cDNA, 15 pmol each of the relevant primers, 200 µmol each of the four deoxynucleoside triphosphates



- 15 -

(dATP, dCTP, dGTP and dTTP) in PCR-buffer (10 mM Tris-HCl pH 8.3 (at 23°C), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001 % gelatine) and 0.5 U AmpliTaq Polymerase (Perkin Elmer). The amplification is performed in the Thermocycler 60 (Biomed) using the following conditions: 0.5 min denaturing at 95°C, 1 min annealing at 56°C, and 1 min 15 sec extension at 72°C, for a total of 20 - 25 cycles. In the last cycle, primer extension at 72°C is carried out for 5 min.

For sequencing and subcloning, the HeLa GT cDNA is amplified in two overlapping pieces, using different primer combinations:

- (1) Fragment P1 - P4: Primers P1 and P4 are used to amplify a DNA fragment covering nucleotide positions 7-555 in the nucleotide sequence depicted in SEQ ID NO. 1.
- (2) Fragment P3 - P2d: Primers P3 and P2d are used to amplify a DNA fragment covering nucleotide positions 457 - 1229 in the nucleotide sequence depicted in SEQ ID NO. 1.

In order to avoid errors during amplification four independent PCRs are carried out for each fragment. Also primer P1up (KpnI) in combination with primer P4 is used to determine the DNA sequence followed by the 'start' codon.

After PCR amplification, fragment P1 - P4 is digested with the restriction enzymes EcoRI and HindIII, analysed on a 1.2 % agarose gel, eluted from the gel by GENECLEAN (BIO 101) and subcloned into the vector pUC18 (Pharmacia), digested with the same enzymes. Fragment P3 - P2d is digested with SacI and EcoRI, analysed on a 1.2 % gel, eluted and subcloned into pUC18, digested with SacI and EcoRI. The resulting subclones are pUC18/P1 - P4 and pUC18/P3 - P2d, respectively. For subcloning, ligation and transformation of *E. coli* strain DH5 $\alpha$ , standard protocols are followed as described in Example 2. Minipreparations of Plasmids pUC18/P1 - P4 and pUC18/P3 - P2d are used for dideoxy-sequencing of denatured double-stranded DNA with the T7 polymerase Sequencing kit (Pharmacia). M13/pUC sequencing primers and reverse sequencing primers (Pharmacia) are applied to sequence overlapping fragments produced from both DNA strands by digestion with various restriction enzymes. Further subcloning of restriction fragments of the GT gene is necessary for extensive sequencing of overlapping fragments of both strands. The sequence of fragments amplified by independent PCRs shows that the error of amplification is less than 1 in 3000 nucleotides. The complete nucleotide sequence of the HeLa cell GT cDNA which is presented in SEQ ID NO. 1 is

- 16 -

99.2 % homologous to that of human placenta (Genbank Accession No. M22921). Three differences are found:

(a) Three extra base pairs at nucleotide positions 37-39 (SEQ ID NO. 1) resulting in one extra amino acid (Ser) in the N-terminal region of the protein; (b) bp 98 to 101 are 'CTCT' instead of 'TCTG' in the sequence of human placenta, leading to two conservative amino acid substitutions (Ala Leu instead of ValTyr) at amino acid positions 31 and 32 in the membrane spanning domain of GT; (c) the nucleotide at position 1047 is changed from 'A' to 'G' without ensuing a change in amino acid sequence.

The two overlapping DNA-fragments P1 - P4 and P3 - P2d encoding the HeLa GT cDNA are joined via the NotI restriction site at nucleotide position 498 which is present in both fragments.

The complete HeLa cell GT cDNA is cloned as a 1.2 kb EcoRI-EcoRI restriction fragment in plasmid pIC-7, a derivative of pUC8 with additional restriction sites in the multicloning site (Marsh, J.L., Erfle, M. and Wykes, E.J. (1984) Gene 32, 481-485), resulting in vector p4AD113. SEQ ID NO. 1 shows the DNA sequence of the EcoRI-HindIII fragment from plasmid p4AD113 comprising HeLa cell cDNA coding for full-length GT (EC 2.4.1.22), said fragment having the following features:

from 6 to 1200 bp	cDNA sequence coding for HeLa cell galactosyltransferase
from 1 to 6 bp	EcoRI site
from 497 to 504 bp	NotI site
from 1227 to 1232 bp	EcoRI site
from 1236 to 1241 bp	EcoRV site
from 1243 to 1248 bp	BglII site

For the purpose of creating the GT expression cassette the EcoRI restriction site (bp 1227) at the 3' end of the cDNA sequence is deleted as follows: vector p4AD113 is first linearized by digestion with EcoRV and then treated with alkaline phosphatase. Furthermore, 1 µg of the linearised plasmid DNA is partially digested with 0.25 U EcoRI for 1 h at 37°C. After agarose gel electrophoresis a fragment corresponding to the size of the linearized plasmid (3.95 kb) is isolated from the gel by GENECLAN (Bio 101). The protruding EcoRI end is filled in with Klenow polymerase as described in the Maniatis manual (supra). After phenolisation and ethanol precipitation the plasmid is religated and used to transform *E. coli* DH5α (Gibco/BRL). Miniprep preparation of plasmids are prepared

- 17 -

from six transformants. The plasmids obtained are checked by restriction analysis for the absence of the EcoRI and EcoRV restriction sites at the 3' end of HeLa GT cDNA. The plasmid designated p4AE113 is chosen for the following experiments, its DNA sequence being identical to that of plasmid p4AD113, with the exception that bp 1232-1238 with the EcoRI-EcoRV restriction sites are deleted.

Example 2: Construction of expression cassettes for full length GT

For heterologous expression in Saccharomyces cerevisiae the full length HeLa GT cDNA sequence (SEQ ID NO. 1) is fused to transcriptional control signals of yeast for efficient initiation and termination of transcription. The promoter and terminator sequences originate from the yeast acid phosphatase gene (PH05) (EP 100561). A short, 173 bp PH05 promoter fragment is used, which is devoid of all regulatory elements and therefore behaves as a constitutive promoter.

The GT cDNA sequence is combined with a yeast 5' truncated PH05 promoter fragment and transcription terminator sequences as follows:

(a) Full length HeLa GT cDNA sequence:

Vector p4AE113 with the full length GT cDNA sequence is digested with the restriction enzymes EcoRI and BglII. The DNA fragments are electrophoretically separated on a 1 % agarose gel. A 1.2 kb DNA fragment containing the complete cDNA sequence for HeLa GT is isolated from the gel by adsorption to glassmilk, using the GENECLEAN kit (BIO 101). On this fragment the 'ATG' start codon for protein synthesis of GT is located directly behind the restriction site for EcoRI, whereas the stop codon 'TAG' is followed by 32 bp contributed by the 3'untranslated region of HeLa GT and the multiple cloning site of the vector with the BglII restriction site.

(b) Vector for amplification in E. coli:

The vector for amplification, plasmid p31R (cf. EP 100561), a derivative of pBR322, is digested with the restriction enzymes BamHI and SalI. The restriction fragments are separated on a 1 % agarose gel and a 3.5 kb vector fragment is isolated from the gel as described before. This DNA fragment contains the large SalI - HindIII vector fragment of the pBR322 derivative as well as a 337 bp PH05 transcription terminator sequence in place of the HindIII - BamHI sequence of pBR322.

(c) Construction of plasmid p31/PH05(-173)RIT

- 18 -

The 5' truncated PHO5 promoter fragment without phosphate regulatory elements is isolated from plasmid p31/PHO5(-173)RIT.

Plasmid p31 RIT12 (EP 288435) comprises the full length, regulated PHO5 promoter (with an EcoRI site introduced at nucleotide position -8 on a 534bp BamHI - EcoRI fragment, followed by the coding sequence for the yeast invertase signal sequence (72bp EcoRI - XhoI) and the PHO5 transcription termination signal (135bp XhoI - HindIII) cloned in a tandem array between BamHI and HindIII of the pBR322 derived vector.

The constitutive PHO5(-173) promoter element from plasmid pJDB207/PHO5(-173)-YHIR (EP 340170) comprises the nucleotide sequence of the yeast PHO5 promoter from nucleotide position -9 to -173 (BstEII restriction site), but has no upstream regulatory sequences (UASp). The PHO5(-173) promoter, therefore, behaves like a constitutive promoter. The regulated PHO5 promoter in plasmid p31RIT12 is replaced by the short, constitutive PHO5 (-173) promoter element in order to obtain plasmid p31/PHO5 (-173) RIT.

Plasmids p31RIT12 (EP 288435) and pJDB207/PHO5(-173)-YHIR (EP 340170) are digested with restriction endonucleases SalI and EcoRI. The respective 3.6 kb and 0.4 kb SalI - EcoRI fragments are isolated on a 0.8 % agarose gel, eluted from the gel, ethanol precipitated and resuspended in H<sub>2</sub>O at a concentration of 0.1 pmoles/μl. Both DNA fragments are ligated and 1 μl aliquots of the ligation mix are used to transform E. coli HB101 (ATCC) competent cells. Ampicillin resistant colonies are grown individually in LB medium supplemented with ampicillin (100 μg/ml). Plasmid DNA is isolated according to the method of Holmes, D.S. et al. (Anal. Biochem. (1981) 144, 193) and analysed by restriction digests with SalI and EcoRI. The plasmid of one clone with the correct restriction fragments is referred to as p31/PHO5(-173)RIT.

(d) Construction of plasmid pGTB1135

Plasmid p31/PHO5(-173)RIT is digested with the restriction enzymes EcoRI and SalI. After separation on a 1 % agarose gel, a 0.45 kb SalI - EcoRI fragment (fragment (c)) is isolated from the gel by GENECLAN (BIO 101). This fragment contains the 276 bp SalI-BamHI sequence of pBR322 and the 173bp BamHI(BstEII)-EcoRI constitutive PHO5 promoter fragment. The 0.45 kb SalI-EcoRI fragment is ligated to the 1.2 kb EcoRI - BglII GT cDNA (fragment (a)) and the 3.5 kb BamHI-SalI vector part for amplification in E. coli with the PHO5 terminator (fragment (b)) described above.

- 19 -

The three DNA fragments (a) to (c) are ligated in a 12 µl ligation mixture: 100 ng of DNA fragment (a) and 30 ng each of fragments (b) and (c) are ligated using 0.3 U T4 DNA ligase (Boehringer) in the supplied ligase buffer (66 mM Tris-HCl pH 7.5, 1 mM dithioerythritol, 5 mM MgCl<sub>2</sub>, 1 mM ATP) at 15°C for 18 hours. Half of the ligation mix is used to transform competent cells of *E. coli* strain DH5α (Gibco/BRL). For preparing competent cells and for transformation, the standard protocol as given in the Maniatis manual (supra) is followed. The cells are plated on selective LB-medium, supplemented with 75 µg/ml ampicillin and incubated at 37°C. 58 transformants are obtained. Minipreparations of plasmid are performed from six independent transformants by using the modified alkaline lysis protocol of Birnboim, H.C. and Doly, J. as described in the Maniatis manual (supra). The isolated plasmids are characterized by restriction analysis with four different enzymes (EcoRI, PstI, HindIII, SalI, also in combination). All six plasmids show the expected fragments. One correct clone is referred to as pGTB 1135. Plasmid pGTB 1135 contains the expression cassette with the full-length HeLaGT cDNA under the control of the constitutive PH05 (-173) promoter fragment, and the PH05 transcriptional terminator sequence. This expression cassette can be excised from vector pGTB 1135 as a 2 kb SalI - HindIII fragment.

### Example 3: Construction of plasmids pA1 and pA2

#### 3.1 PCR for site-directed mutagenesis

In order to knock out the stop codon of the GT coding sequence and to allow for an in frame fusion with ST a frame shift mutation and a point mutation are introduced into the cDNA coding for HeLa GT. The oligonucleotide primers used for PCR are synthesized in vitro according to the phosphoramidite method (supra) and listed in Table 2.

Table 2: PCR-primers

primer	sequence (5' to 3') <sup>1)</sup>	corresponding to bp in SEQ ID NO.3
P3 (SacI)	CTGGAGCTCGTGGCAAAGCAGAACCC	457 - 482
P2A1 (BamHI)	ggggaTCCTAGCTCG-TGTCCC	1205 - 1189
P2B1 (BamHI)	ggggaTCCAGCTCG-TGTCCC	1205 - 1189

<sup>1)</sup> Capital letters represent sequences from GT, small letters are additional sequences, sites for restriction enzymes are underlined. Codons for 'start' and 'stop' of RNA translation are highlighted in boldface.

- 20 -

Standard PCR-conditions for a 30 µl incubation mixture are: 1 µl of the Reverse Transcriptase reaction mix containing about 5 ng first strand cDNA (see Example 1.2), 15 pmol each of the relevant primers, 200 µmol each of the four deoxynucleoside triphosphates (dATP, dCTP, dGTP and dTTP) in PCR-buffer (10 mM Tris-HCl pH 8.3 (at 23°C), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001 % gelatine) and 0.5 U AmpliTaq Polymerase (Perkin Elmer). The amplification is performed in the Thermocycler 60 (Biomed) using the following conditions: 0.5 min denaturing at 95°C, 1 min annealing at 56°C, and 1 min 15 sec extension at 72°C, for a total of 20 - 25 cycles. In the last cycle, primer extension at 72°C is carried out for 5 min.

For sequencing and subcloning, the HeLa GT cDNA is amplified as described above, yielding "mutated" fragments:

- (3) Fragment P3-P2A1: primers P3 and P2A1 are used to amplify a 0.77 kb fragment covering nucleotides 457-1205 in the sequence depicted in SEQ ID NO. 3
- (4) Fragment P3-P2B1: primers P3 and P2B1 are used to amplify a 0.77 kb fragment covering nucleotide positions 457-1205 in the sequence depicted in SEQ ID NO. 3.

### 3.2 Construction of plasmids pA1 and pA2

Fragments P3-P2A1 and P3-P2B1, respectively, are amplified by PCR, digested with BamHI and SacI and subcloned into vector pUC18 (Pharmacia), digested with the same enzyme to produce plasmids pA1 and pA2.

#### Example 4: Cloning of the sialyltransferase (ST) cDNA from human HepG2 cells

ST cDNA is isolated from HepG2 cells by PCR in analogy to GT cDNA. Preparation of poly (A)<sup>+</sup>RNA and first strand cDNA synthesis are performed as described in Example 1. The primers (Microsynth) listed in Table 3 are used for PCR.

- 21 -

Table 3: PCR-primers

primer	sequence (5' to 3') <sup>1)</sup>	corresponding to bp in ST cDNA <sup>2)</sup>
<b>PstI/EcoRI</b>		
SIA1	<u>cgctgcagaattcaaaa</u> <b>ATGATT</b> CACACCAACCTGAAGAAAAAGT	1 - 28
<b>BamHI</b>		
SIA3	<u>cgcggaatCCT</u> GTGCTTAGCAGTGAATGGTCCGGAAGCC	1218 - 1198

- 1) Capital letters represent sequences from ST, small letters are additional sequences with sites for restriction enzymes (underlined). Codons for 'start' and 'stop' for protein synthesis are indicated in boldface.  
 2) ST cDNA sequence from human placenta as published in EMBL Data Bank (Accession No. X17247)

HepG2 ST cDNA can be amplified as one DNA fragment of 1.2 kb using the primers SIA1 and SIA3. PCR is performed as described for GT cDNA under slightly modified cycling conditions: 0.5 min denaturing at 95°C, 1 min. 15 sec annealing at 56°C, and 1 min 30 sec extension at 72°C, for a total of 25-35 cycles. In the last cycle, primer extension at 72°C is carried out for 5 min.

After PCR amplification, the 1.2 kb fragment is digested with the restriction enzymes BamHI and PstI, analysed on a 1.2 % agarose gel, eluted from the gel and subcloned into the vector pUC18. The resulting subclone is designated pSIA2. The nucleotide sequence of the PstI-BamHI fragment from plasmid pSIA2 comprising HepG2 cDNA coding for full-length sialyltransferase is presented in SEQ ID NO. 3, said fragment having the following features:

from 15 to 1232 bp	cDNA sequence coding for HepG2 cell sialyltransferase
from 1 to 6 bp	PstI site
from 6 to 11 bp	EcoRI site
from 144 to 149 bp	EcoRI site
from 1241 to 1246 bp	BamHI site.

#### Example 5: Construction of plasmids pA1ST and pB1ST

a) Plasmid pSIA2 is double digested using EcoRI/BamHI and the ensuing 1098 bp fragment (fragment (a)) is isolated. The fragment codes for a soluble ST designated ST<sub>(44-406)</sub> starting at amino acid position 44 (Glu) and extending to amino acid position

- 22 -

406 (Cys) (SEQ ID NO. 4).

b) Plasmids A1 and B1 are linearized by BamHI digestion, treated with alkaline phosphatase and separated from contaminating enzymes by gel electrophoresis using GENECLAN (Bio 101).

c) Fragment (a) is linked to fragment (b) by means of an adaptor sequence from equimolar amounts of the synthesized oligonucleotides (Microsynth):

5' GATCCGTCGACCTGCAG 3' and 5' AATTCAGCAGGTCGACG 3' for the complementary strand. The oligonucleotides are annealed to each other by first heating to 95°C and then slowly cooling to 20°C. Ligation is carried out in 12 µl of ligase buffer (66 mM Tris-HCl pH 7.5, 1 mM dithioerythritol, 5 mM MgCl<sub>2</sub>, 1 mM ATP) at 16°C for 18 hours. The sequences at the junction of GT and ST are as follows:

pA1ST:                      BamHI    Adaptor (bold)    EcoRI  
GGG ACA CGA GCT AGG **ATC CGT CGA CCT GCA GAA TTC** CAG GTG  
Gly Thr Arg Ala Arg Ile Arg Arg Pro Ala Glu Phe Gln Val

pB1ST:  
GGG ACA CGA GCT GGG **ATC CGT CGA CCT GCA GAA TTC** CAG GTG  
Gly Thr Arg Ala Gly Ile Arg Arg Pro Ala Glu Phe Gln Val

The ligated plasmids pA1ST and pB1ST are transformed into E. coli strain DH5α. Plasmid DNA of 6 transformants from each transformation is isolated and digested with EcoRI to test the orientation of the BamHI insert. Plasmids with a 3900 bp together with a 700 bp EcoRI fragment are used for the next step.

#### Example 6: Construction of the GT-ST expression vectors YEPGSTa and YEPGSTb

##### 6.1 Isolation of a NotI-BamHI fragment coding for the GT C-terminus fused to ST

Plasmids pA1ST and pB1ST are linearised by cutting with NotI and then partially digested with BamHI. After gel electrophoresis a 1900 bp NotI-BamHI fragment coding for the GT C-terminus fused to ST is isolated.

##### 6.2 Construction of the YEPGTB vector

The episomal yeast vector YEP352 (S.E. Hill et al., Yeast 2, 163-167, 1986) is used to construct the YEPGTB vector which contains the constitutive PHO5 promoter, the cDNA coding for full length GT and the PHO5 transcriptional terminator sequence.

YEP352 is digested with the restriction enzymes Sall and HindIII at the multiple cloning site. After separation over an 0.8% agarose gel the linearized vector is isolated as a 5.2 kb DNA fragment (vector part) from the gel with the GENECLAN kit (Bio 101). Vector



- 23 -

pGTB1135 (Example 2) is also digested with the restriction enzymes SalI and HindIII. A 2.0 kb fragment containing the expression cassette with the constitutive promoter is isolated. Ligation of the yeast vector and the expression cassette is carried out as follows: in a 12 µl ligation mix, 80 ng of the vector part (5.2 kb fragment) is combined with 40 ng of the 2.0 kb SalI-HindIII fragment using 0.3U ligase (Boehringer) in the supplied buffer (66 mM Tris-HCl pH 7.5, 1 mM dithioerythritol, 5 mM MgCl<sub>2</sub>, 1 mM ATP) for 18 hours at 15°C. The ligation mix is used to transform E.coli DH5α as described above. 24 transformants are obtained. Four independent colonies are chosen for miniprep preparation of plasmids. The isolated plasmids are characterized by restriction analysis: all four analyzed plasmids (YEPGTB 21-24) show the expected restriction patterns. YEPGTB24 is used for further experiments.

#### 6.3 Isolation of the fragment coding for the N-terminal part of GT.

YEPGTB24 carrying the whole constitutive expression cassette for GT in the yeast-E.coli shuttle vector YEP352 is cut with NotI and HindIII and a 6.3 kb fragment is isolated after gel electrophoresis.

#### 6.4 PHO5-terminator sequence

Plasmid p31 RIT12 (EP 288435) is cut with BamHI and Hind III and a 400 bp fragment carrying the PHO5 terminator sequence is isolated.

Fragments isolated as described in 6.1 (1.9 kb NotI-BamHI fragment, 6.3 (6.3 kb HindIII-NotI fragment) and 6.4 (0.4 kb BamHI-HindIII fragment) are ligated to yield plasmids YEPGSTa and YEPGSTb, respectively, which are transformed in the E.coli strain DH5α. Plasmid DNA of transformants carrying the predicted pattern of BamHI fragments with 5580 bp, 1375 bp, 1150bp and 276 bp are used for yeast transformation. The nucleotide sequences of the cDNAs coding for the hybrid glycosyltransferases designated GT-STa and GT-STb are presented in SEQ ID NOs. 5 and 7, respectively, said sequences having the following common features:

from 1 to 1188 bp	cDNA sequence coding for HeLa cell GT <sub>(1-396)</sub> (cf. SEQ ID NO.1)
from 1189 to 1212 bp	Adaptor
from 1213 to 2301 bp	cDNA sequence coding for HepG2 cell ST <sub>(44-406)</sub>

- 24 -

#### Example 7: Transformation of yeast strain BT 150

CsCl-purified DNA of the expression vectors YEPGSTa and YEPGSTb is prepared following the protocol of R. Treisman in the Maniatis manual (supra). The protease deficient *S. cerevisiae* strain BT 150 (MAT $\alpha$ , his4, leu2, ura3, pral, prb1, prc1, cps1) is transformed with about 1  $\mu$ g of plasmids YEPGSTa and YEPGSTb, respectively, according to the lithium-acetate transformation method (Ito et al., J. Bact. (1983) 153, 163-168). Approximately 200 transformants are obtained with YEPGSTa and YEPGSTb on SD plates (0.67% yeast nitrogen base without amino acids, 2% glucose, 2% agarose supplemented with leucine (30  $\mu$ g/ml) and histidine (20  $\mu$ g/ml). Single transformed yeast cells are selected and referred to as *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb, respectively.

#### Example 8: Enzyme activity of the GT-ST hybrid proteins

##### 8.1 Preparation of cell extracts

##### Preparation of cell extracts

Cells of transformed *Saccharomyces cerevisiae* strains BT 150 are each grown under uracil selection in yeast minimal media (Difco) supplemented with histidine and leucine. The growth rate of the cells is not affected by the introduction of any of the expression vectors. Exponentially growing cells (at OD<sub>578</sub> of 2.0) or stationary cells are collected by centrifugation, washed once with 50 mM Tris-HCl buffer pH 7.4 (buffer 1) and resuspended in buffer 1 at a concentration corresponding to 2 OD<sub>578</sub>. A 60 ml culture (120 OD<sub>578</sub>) of yeast cells is washed, pelleted and subjected to mechanical breakage by vigorous shaking on a vortex mixer with glass beads (0.45 - 0.5 mm diameter) for 4 min with intermittent cooling. The crude extracts are used directly for determination of enzyme activity.

##### 8.2 Protein assay

The protein concentration is determined by use of the BCA-Protein Assay Kit (Pierce).

##### 8.3 Assay for GT activity

GT activity can be measured with radiochemical methods using either ovalbumin, a glycoprotein which solely exposes GlcNAc as acceptor site, or free GlcNAc as acceptor substrates. Cell extracts (of 1 - 2 ODs<sub>578</sub> of cells) are assayed for 30 min at 37°C in a 100  $\mu$ l incubation mixture containing 35 mM Tris-HCl pH 7.4, 25 nCi UDP-<sup>14</sup>C-Gal (1.25 mCi/mmol), 1  $\mu$ mol MnCl<sub>2</sub>, 2 % Triton X-100 and 1 mg ovalbumin or 20 mM GlcNAc as acceptor substrates. The reaction is terminated by acid precipitation of the

- 25 -

protein and the amount of  $^{14}\text{C}$  galactose incorporated into ovalbumin is determined by liquid scintillation counting (Berger, E.G. et al. (1978) Eur. J. Biochem. 90, 213-222). For GlcNAc as acceptor substrate, the reaction is terminated by the addition of 0.4 ml ice cold  $\text{H}_2\text{O}$  and the unused UDP- $^{14}\text{C}$ -galactose is separated from  $^{14}\text{C}$  products on an anion exchange column (AG X1-8, BioRad) as described (Masibay, A.S. and Qasba, P.K. (1989) Proc. Natl. Acad. Sci. USA 86, 5733-5737). Assays are performed with and without acceptor molecules to assess the extent of hydrolysis of UDP-Gal by nucleotide pyrophosphatases. GT activity is determined in the crude extracts prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb.

#### 8.4 Determination of optimum detergent activation

The standard assay of GT activity according to Example 8.3 using 10 mM GlcNAc as acceptor substrate is carried out in presence of zero, 0.1, 0.5, 1.0, 2.0, 2.5 and 4 % Triton X-100 in the assay. 2 % Triton X-100 induce a two fold stimulation as compared with zero % Triton.

#### 8.5 Assay for lactose synthase activity

The assay is carried out and terminated as indicated in Example 8.3 for GlcNAc as acceptor with the following modifications: instead of GlcNAc, 30 mM glucose is used as acceptor. Other ingredients include: 1 mg/ml human  $\alpha$ -lactalbumin, 10 mM ATP. Optimum concentration of  $\alpha$ -lactalbumin is determined in a range of 0 to 4 mg/ml  $\alpha$ -lactalbumin. Maximum lactose synthase activity is observed at 1 mg/ml.

#### 8.6 Assay for ST activity

ST activity can be determined by measuring the amount of radiolabeled sialic acid which is transferred from CMP-sialic acid to a glycoprotein acceptor. In case of the use of a glycoprotein as acceptor such as asialofetuin, the reaction is terminated by acid precipitation using 5% (w/v) phosphotungstic acid and 5% (w/v) trichloroacetic acid. The precipitate is filtered using glass fiber filters (Whatman GFA), washed extensively with ice-cold ethanol and assessed for radioactivity by liquid scintillation counting (Hesford et al. (1984), Glycoconjugate J. 1, 141-153). In case of the use of oligosaccharides as acceptors such as lactose or LacNAc (N-acetyllactosamin), the reaction is terminated by addition of 0.4 ml ice-cold  $\text{H}_2\text{O}$ . The unused CMP- $^{14}\text{C}$ -sialic acid is retained on a 1 ml-column of AG1-X8, phosphate form, 100-200 mesh. The column is washed with 4.5 ml  $\text{H}_2\text{O}$  and eluted with 24 ml 5 mM  $\text{K}_2\text{HPO}_4$  buffer at pH 6.8. Eluant and wash

solution are pooled and assessed for radioactivity by liquid scintillation counting. Standard conditions are as follows: 20  $\mu$ l of yeast extracts (200 to 500  $\mu$ g protein) are incubated with 300  $\mu$ g asialofetuin in 2 mM imidazole buffer pH 7.4 and 3 nmoles CMP- $^{14}$ C-sialic acid (specific activity: 2.7 mCi/mmol), Triton X-100 0.5 %. ST-activity is found in the crude extracts prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb.

#### 8.7 Combined GT and ST activity

Yeast extracts prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb are used to transfer Gal from UDPGal and sialic acid from CMPNeuAc to asialo-agalacto- $\alpha_1$  acid glycoprotein or GlcNAc according to the following conditions: 30  $\mu$ l of extract, 20  $\mu$ l of asialo-agalacto- $\alpha_1$  acid glycoprotein (prepared according to Hughes, R.C. and Jeanloz, R.W., (1966), *Biochemistry* 5, 253-258), 2 mM of unlabeled UDPGal, 60  $\mu$ M of CMP $^{14}$ C-sialic acid (specific activity: 5.4 mCi/mmol) in 2 mM imidazole buffer, pH 7.4. ST-activity is shown by incorporation of  $^{14}$ C-sialic acid. Control incubation carried out in the absence of unlabeled UDPGal results in a 4 times less incorporation of  $^{14}$ C-sialic acid.

Similar incubations are carried out using 20 mM GlcNAc or 30 mM glucose (in presence of 0.1 mg/ml  $\alpha$ -lactalbumin) as acceptor and isolating the product according to 8.6. Linear incorporations of  $^{14}$ C-sialic acid are observed during 180 min. The assay system contains in a final volume of 1 ml: 3 mmol glucose, 1 mg  $\alpha$ -lactalbumin, 1 mM ATP, 1 mmol  $\text{MnCl}_2$ , 20 mmol Tris-HCl, pH 7.4, 20 nmol UDPGal, 12 nmol CMP $^{14}$ C-sialic acid (4.4 mCi/mmol specific activity) and 350  $\mu$ g protein (yeast extract). The reaction is terminated by adding 0.4 ml of ice-cold  $\text{H}_2\text{O}$ . The mixture is passed over a 2 cm Bio-Rad Poly-Prep<sup>R</sup> column containing AG1-X8 A6, 100-200 mesh, phosphate form. The column is washed with 4.5 ml  $\text{H}_2\text{O}$  and eluted with 24 ml 5mM  $\text{K}_2\text{HPO}_4$  buffer at pH 6.8. 1 ml of the eluant is used for radioactivity measurement by liquid scintillation counting in 10 ml Instagel<sup>R</sup>.

#### 8.8 Product identification of oligosaccharides synthesized by the GT-ST hybrid proteins

##### 8.8.1 Synthesis of 2,6 sialyllacNAc

The incubation mixture contains in a volume of 1.57 ml: 20 mmol GlcNAc, 10 mM ATP, 1 mMol  $\text{MnCl}_2$ , 5 mg Triton X-100, 200 mMol UDPGal, 30 mmol CMP  $^{14}$ C-sialic acid (4.4 mCi/mmol specific activity) and 1000  $\mu$ g protein (yeast extract prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb, respectively). Incubation is carried out for 16 h at 37°C. The reaction is

- 27 -

terminated by adding 0.5 ml of H<sub>2</sub>O. The incubation mixture is separated on AG1-X8 as described in Example 8.7. The total eluant of the anion exchange column is lyophilized. Then, the residue is dissolved in 0.6 ml H<sub>2</sub>O followed by separation on a Biogel P2 column (200-400 mesh, 2x90 cm). The column is eluted with H<sub>2</sub>O at a temperature of 42.5°C at 5 ml/h. 0.5 ml fractions are collected and assessed for radioactivity in 100 µl aliquots (to which 4 ml Instagel<sup>R</sup> is added for liquid scintillation counting). The peak fractions containing <sup>14</sup>C are pooled, lyophilized and repurified on AG1-X8 as described in Example 8.7. The total eluant of 24 ml is lyophilized, the resulting residue dissolved in 300 µl H<sub>2</sub>O. This solution is subjected to preparative thin layer chromatography (Merck Alu plates coated with silicagel 60 F<sub>254</sub>) in a solvent system containing H<sub>2</sub>O/acetone/n-butanol 2/1.5/1.5 for 5 h and run against authentic standards including 50 mM sialyl 2,6-lactose and 2,6 sialyl LacNAc. After drying the products and standards are visualized using a spray containing 0.5 g thymol in 5 ml H<sub>2</sub>SO<sub>4</sub> (96 %) and 95 ml ethanol (96 %) followed by heating for 10 min at 130°C. The spots detected are found to be at identical positions as the corresponding authentic standards.

- 28 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: CIBA-GEIGY AG
- (B) STREET: Klybeckstr. 141
- (C) CITY: Basel
- (E) COUNTRY: SCHWEIZ
- (F) POSTAL CODE (ZIP): 4002
- (G) TELEPHONE: +41 61 69 11 11
- (H) TELEFAX: + 41 61 696 79 76
- (I) TELEX: 962 991

(ii) TITLE OF INVENTION: Proteins having glycosyltransferase activity

(iii) NUMBER OF SEQUENCES: 8

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1265 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 29 -

## (vi) ORIGINAL SOURCE:

(B) STRAIN: E. coli DH5alpha

## (vii) IMMEDIATE SOURCE:

(B) CLONE: p4AD113

## (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 7..1200

(D) OTHER INFORMATION: /product= "full-length  
galactosyltransferase"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTC ATG AGG CTT CGG GAG CCG CTC CTG AGC GGC AGC GCC GCG ATG	48
Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met	
1 5 10	
CCA GGC GCG TCC CTA CAG CGG GCC TGC CGC CTG CTC GTG GCC GTC TGC	96
Pro Gly Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys	
15 20 25 30	
GCT CTG CAC CTT GGC GTC ACC CTC GTT TAC TAC CTG GCT GGC CGC GAC	144
Ala Leu His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp	
35 40 45	
CTG AGC CGC CTG CCC CAA CTG GTC GGA GTC TCC ACA CCG CTG CAG GGC	192
Leu Ser Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly	
50 55 60	
GGC TCG AAC AGT GCC GCC GCC ATC GGG CAG TCC TCC GGG GAG CTC CGG	240
Gly Ser Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg	
65 70 75	

- 30 -

ACC GGA GGG GCC CGG CCG CCG CCT CCT CTA GGC GCC TCC TCC CAG CCG	288
Thr Gly Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro	
80 85 90	
CGC CCG GGT GGC GAC TCC AGC CCA GTC GTG GAT TCT GGC CCT GGC CCC	336
Arg Pro Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro	
95 100 105 110	
GCT AGC AAC TTG ACC TCG GTC CCA GTG CCC CAC ACC ACC GCA CTG TCG	384
Ala Ser Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser	
115 120 125	
CTG CCC GCC TGC CCT GAG GAG TCC CCG CTG CTT GTG GGC CCC ATG CTG	432
Leu Pro Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu	
130 135 140	
ATT GAG TTT AAC ATG CCT GTG GAC CTG GAG CTC GTG GCA AAG CAG AAC	480
Ile Glu Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn	
145 150 155	
CCA AAT GTG AAG ATG GGC GGC CGC TAT GCC CCC AGG GAC TGC GTC TCT	528
Pro Asn Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser	
160 165 170	
CCT CAC AAG GTG GCC ATC ATC ATT CCA TTC CGC AAC CGG CAG GAG CAC	576
Pro His Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His	
175 180 185 190	
CTC AAG TAC TGG CTA TAT TAT TTG CAC CCA GTC CTG CAG CGC CAG CAG	624
Leu Lys Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln	
195 200 205	
CTG GAC TAT GGC ATC TAT GTT ATC AAC CAG GCG GGA GAC ACT ATA TTC	672
Leu Asp Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe	
210 215 220	



- 31 -

AAT CGT GCT AAG CTC CTC AAT GTT GGC TTT CAA GAA GCC TTG AAG GAC 720  
 Asn Arg Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp  
 225 230 235

TAT GAC TAC ACC TGC TTT GTG TTT AGT GAC GTG GAC CTC ATT CCA ATG 768  
 Tyr Asp Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met  
 240 245 250

AAT GAC CAT AAT GCG TAC AGG TGT TTT TCA CAG CCA CGG CAC ATT TCC 816  
 Asn Asp His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser  
 255 260 265 270

GTT GCA ATG GAT AAG TTT GGA TTC AGC CTA CCT TAT GTT CAG TAT TTT 864  
 Val Ala Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe  
 275 280 285

GGA GGT GTC TCT GCT CTA AGT AAA CAA CAG TTT CTA ACC ATC AAT GGA 912  
 Gly Gly Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly  
 290 295 300

TTT CCT AAT AAT TAT TGG GGC TGG GGA GGA GAA GAT GAT GAC ATT TTT 960  
 Phe Pro Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe  
 305 310 315

AAC AGA TTA GTT TTT AGA GGC ATG TCT ATA TCT CGC CCA AAT GCT GTG 1008  
 Asn Arg Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val  
 320 325 330

GTC GGG AGG TGT CGC ATG ATC CGC CAC TCA AGA GAC AAG AAA AAT GAA 1056  
 Val Gly Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu  
 335 340 345 350

CCC AAT CCT CAG AGG TTT GAC CGA ATT GCA CAC ACA AAG GAG ACA ATG 1104  
 Pro Asn Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met  
 355 360 365

- 32 -

CTC TCT GAT GGT TTG AAC TCA CTC ACC TAC CAG GTG CTG GAT GTA CAG 1152  
 Leu Ser Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln  
 370 375 380

AGA TAC CCA TTG TAT ACC CAA ATC ACA GTG GAC ATC GGG ACA CCG AGC 1200  
 Arg Tyr Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Pro Ser  
 385 390 395

TAGGACTTTT GGTACAGGTA AAGACTGAAT TCATCGATAT CTAGATCTCG AGCTCGCGAA 1260  
 AGCTT 1265

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 398 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly  
 1 5 10 15

Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu  
 20 25 30

His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser  
 35 40 45

Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser  
 50 55 60

- 33 -

Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly  
 65 70 75 80

Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro  
 85 90 95

Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser  
 100 105 110

Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro  
 115 120 125

Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
 130 135 140

Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
 145 150 155 160

Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
 165 170 175

Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
 180 185 190

Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
 195 200 205

Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
 210 215 220

Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
 225 230 235 240

Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
 245 250 255

- 34 -

His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
                   260                                  265                                  270

Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
                   275                                  280                                  285

Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
                   290                                  295                                  300

Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
                   305                                  310                                  315                                  320

Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
                                   325                                  330                                  335

Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
                   340                                  345                                  350

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser  
                   355                                  360                                  365

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr  
                   370                                  375                                  380

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Pro Ser  
                   385                                  390                                  395

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1246 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 35 -

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

(B) CLONE: pSIA2

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 15..1232

(D) OTHER INFORMATION: /product= "full-length  
sialyltransferase (EC 2.4.99.1)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CTGCAGAATT CAAA ATG ATT CAC ACC AAC CTG AAG AAA AAG TTC AGC TGC	50
Met Ile His Thr Asn Leu Lys Lys Lys Phe Ser Cys	
1 5 10	
TGC GTC CTG GTC TTT CTT CTG TTT GCA GTC ATC TGT GTG TGG AAG GAA	98
Cys Val Leu Val Phe Leu Leu Phe Ala Val Ile Cys Val Trp Lys Glu	
15 20 25	
AAG AAG AAA GGG AGT TAC TAT GAT TCC TTT AAA TTG CAA ACC AAG GAA	146
Lys Lys Lys Gly Ser Tyr Tyr Asp Ser Phe Lys Leu Gln Thr Lys Glu	
30 35 40	
TTC CAG GTG TTA AAG AGT CTG GGG AAA TTG GCC ATG GGG TCT GAT TCC	194
Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala Met Gly Ser Asp Ser	
45 50 55 60	
CAG TCT GTA TCC TCA AGC AGC ACC CAG GAC CCC CAC AGG GGC CGC CAG	242
Gln Ser Val Ser Ser Ser Ser Thr Gln Asp Pro His Arg Gly Arg Gln	
65 70 75	

- 36 -

ACC CTC GGC AGT CTC AGA GGC CTA GCC AAG GCC AAA CCA GAG GCC TCC	290
Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala Lys Pro Glu Ala Ser	
80 85 90	
TTC CAG GTG TGG AAC AAG GAC AGC TCT TCC AAA AAC CTT ATC CCT AGG	338
Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys Asn Leu Ile Pro Arg	
95 100 105	
CTG CAA AAG ATC TGG AAG AAT TAC CTA AGC ATG AAC AAG TAC AAA GTG	386
Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met Asn Lys Tyr Lys Val	
110 115 120	
TCC TAC AAG GGG CCA GGA CCA GGC ATC AAG TTC AGT GCA GAG GCC CTG	434
Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe Ser Ala Glu Ala Leu	
125 130 135 140	
CGC TGC CAC CTC CGG GAC CAT GTG AAT GTA TCC ATG GTA GAG GTC ACA	482
Arg Cys His Leu Arg Asp His Val Asn Val Ser Met Val Glu Val Thr	
145 150 155	
GAT TTT CCC TTC AAT ACC TCT GAA TGG GAG GGT TAT CTG CCC AAG GAG	530
Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly Tyr Leu Pro Lys Glu	
160 165 170	
AGC ATT AGG ACC AAG GCT GGG CCT TGG GGC AGG TGT GCT GTT GTG TCG	578
Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg Cys Ala Val Val Ser	
175 180 185	
TCA GCG GGA TCT CTG AAG TCC TCC CAA CTA GGC AGA GAA ATC GAT GAT	626
Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly Arg Glu Ile Asp Asp	
190 195 200	
CAT GAC GCA GTC CTG AGG TTT AAT GGG GCA CCC ACA GCC AAC TTC CAA	674
His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro Thr Ala Asn Phe Gln	
205 210 215 220	

- 37 -

CAA GAT GTG GGC ACA AAA ACT ACC ATT CGC CTG ATG AAC TCT CAG TTG 722  
 Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu Met Asn Ser Gln Leu  
 225 230 235

GTT ACC ACA GAG AAG CGC TTC CTC AAA GAC AGT TTG TAC AAT GAA GGA 770  
 Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser Leu Tyr Asn Glu Gly  
 240 245 250

ATC CTA ATT GTA TGG GAC CCA TCT GTA TAC CAC TCA GAT ATC CCA AAG 818  
 Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His Ser Asp Ile Pro Lys  
 255 260 265

TGG TAC CAG AAT CCG GAT TAT AAT TTC TTT AAC AAC TAC AAG ACT TAT 866  
 Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn Asn Tyr Lys Thr Tyr  
 270 275 280

CGT AAG CTG CAC CCC AAT CAG CCC TTT TAC ATC CTC AAG CCC CAG ATG 914  
 Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile Leu Lys Pro Gln Met  
 285 290 295 300

CCT TGG GAG CTA TGG GAC ATT CTT CAA GAA ATC TCC CCA GAA GAG ATT 962  
 Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile Ser Pro Glu Glu Ile  
 305 310 315

CAG CCA AAC CCC CCA TCC TCT GGG ATG CTT GGT ATC ATC ATC ATG ATG 1010  
 Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly Ile Ile Ile Met Met  
 320 325 330

ACG CTG TGT GAC CAG GTG GAT ATT TAT GAG TTC CTC CCA TCC AAG CGC 1058  
 Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe Leu Pro Ser Lys Arg  
 335 340 345

AAG ACT GAC GTG TGC TAC TAC TAC CAG AAG TTC TTC GAT AGT GCC TGC 1106  
 Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe Phe Asp Ser Ala Cys  
 350 355 360

- 38 -

ACG ATG GGT GCC TAC CAC CCG CTG CTC TAT GAG AAG AAT TTG GTG AAG 1154  
 Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu Lys Asn Leu Val Lys  
 365 370 375 380

CAT CTC AAC CAG GGC ACA GAT GAG GAC ATC TAC CTG CTT GGA AAA GCC 1202  
 His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr Leu Leu Gly Lys Ala  
 385 390 395

ACA CTG CCT GGC TTC CGG ACC ATT CAC TGC TAAGCACAGG ATCC 1246  
 Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
 400 405

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 406 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Ile His Thr Asn Leu Lys Lys Lys Phe Ser Cys Cys Val Leu Val  
 1 5 10 15

Phe Leu Leu Phe Ala Val Ile Cys Val Trp Lys Glu Lys Lys Gly  
 20 25 30

Ser Tyr Tyr Asp Ser Phe Lys Leu Gln Thr Lys Glu Phe Gln Val Leu  
 35 40 45

Lys Ser Leu Gly Lys Leu Ala Met Gly Ser Asp Ser Gln Ser Val Ser  
 50 55 60



- 39 -

Ser Ser Ser Thr Gln Asp Pro His Arg Gly Arg Gln Thr Leu Gly Ser  
65 70 75 80

Leu Arg Gly Leu Ala Lys Ala Lys Pro Glu Ala Ser Phe Gln Val Trp  
85 90 95

Asn Lys Asp Ser Ser Ser Lys Asn Leu Ile Pro Arg Leu Gln Lys Ile  
100 105 110

Trp Lys Asn Tyr Leu Ser Met Asn Lys Tyr Lys Val Ser Tyr Lys Gly  
115 120 125

Pro Gly Pro Gly Ile Lys Phe Ser Ala Glu Ala Leu Arg Cys His Leu  
130 135 140

Arg Asp His Val Asn Val Ser Met Val Glu Val Thr Asp Phe Pro Phe  
145 150 155 160

Asn Thr Ser Glu Trp Glu Gly Tyr Leu Pro Lys Glu Ser Ile Arg Thr  
165 170 175

Lys Ala Gly Pro Trp Gly Arg Cys Ala Val Val Ser Ser Ala Gly Ser  
180 185 190

Leu Lys Ser Ser Gln Leu Gly Arg Glu Ile Asp Asp His Asp Ala Val  
195 200 205

Leu Arg Phe Asn Gly Ala Pro Thr Ala Asn Phe Gln Gln Asp Val Gly  
210 215 220

Thr Lys Thr Thr Ile Arg Leu Met Asn Ser Gln Leu Val Thr Thr Glu  
225 230 235 240

Lys Arg Phe Leu Lys Asp Ser Leu Tyr Asn Glu Gly Ile Leu Ile Val  
245 250 255

- 40 -

Trp Asp Pro Ser Val Tyr His Ser Asp Ile Pro Lys Trp Tyr Gln Asn  
 260 265 270

Pro Asp Tyr Asn Phe Phe Asn Asn Tyr Lys Thr Tyr Arg Lys Leu His  
 275 280 285

Pro Asn Gln Pro Phe Tyr Ile Leu Lys Pro Gln Met Pro Trp Glu Leu  
 290 295 300

Trp Asp Ile Leu Gln Glu Ile Ser Pro Glu Glu Ile Gln Pro Asn Pro  
 305 310 315 320

Pro Ser Ser Gly Met Leu Gly Ile Ile Ile Met Met Thr Leu Cys Asp  
 325 330 335

Gln Val Asp Ile Tyr Glu Phe Leu Pro Ser Lys Arg Lys Thr Asp Val  
 340 345 350

Cys Tyr Tyr Tyr Gln Lys Phe Phe Asp Ser Ala Cys Thr Met Gly Ala  
 355 360 365

Tyr His Pro Leu Leu Tyr Glu Lys Asn Leu Val Lys His Leu Asn Gln  
 370 375 380

Gly Thr Asp Glu Asp Ile Tyr Leu Leu Gly Lys Ala Thr Leu Pro Gly  
 385 390 395 400

Phe Arg Thr Ile His Cys  
 405

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2304 base pairs

(B) TYPE: nucleic acid

- 41 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

(B) CLONE: YEPGSTa

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..2301

(D) OTHER INFORMATION: /product=

"galactosyltransferase-sialyltransferase hybrid  
protein"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATG AGG CTT CGG GAG CCG CTC CTG AGC GGC AGC GCC GCG ATG CCA GGC	48
Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly	
1 5 10 15	
GCG TCC CTA CAG CGG GCC TGC CGC CTG CTC GTG GCC GTC TGC GCT CTG	96
Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu	
20 25 30	
CAC CTT GGC GTC ACC CTC GTT TAC TAC CTG GCT GGC CGC GAC CTG AGC	144
His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser	
35 40 45	
CGC CTG CCC CAA CTG GTC GGA GTC TCC ACA CCG CTG CAG GGC GGC TCG	192
Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser	
50 55 60	

- 42 -

AAC AGT GCC GCC GCC ATC GGG CAG TCC TCC GGG GAG CTC CGG ACC GGA 240  
 Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly  
 65 70 75 80

GGG GCC CGG CCG CCG CCT CCT CTA GGC GCC TCC TCC CAG CCG CGC CCG 288  
 Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro  
 85 90 95

GGT GGC GAC TCC AGC CCA GTC GTG GAT TCT GGC CCT GGC CCC GCT AGC 336  
 Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser  
 100 105 110

AAC TTG ACC TCG GTC CCA GTG CCC CAC ACC ACC GCA CTG TCG CTG CCC 384  
 Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro  
 115 120 125

GCC TGC CCT GAG GAG TCC CCG CTG CTT GTG GGC CCC ATG CTG ATT GAG 432  
 Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
 130 135 140

TTT AAC ATG CCT GTG GAC CTG GAG CTC GTG GCA AAG CAG AAC CCA AAT 480  
 Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
 145 150 155 160

GTG AAG ATG GGC GGC CGC TAT GCC CCC AGG GAC TGC GTC TCT CCT CAC 528  
 Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
 165 170 175

AAG GTG GCC ATC ATC ATT CCA TTC CGC AAC CGG CAG GAG CAC CTC AAG 576  
 Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
 180 185 190

TAC TGG CTA TAT TAT TTG CAC CCA GTC CTG CAG CGC CAG CAG CTG GAC 624  
 Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
 195 200 205

- 43 -

TAT GGC ATC TAT GTT ATC AAC CAG GCG GGA GAC ACT ATA TTC AAT CGT 672  
 Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
 210 215 220

GCT AAG CTC CTC AAT GTT GGC TTT CAA GAA GCC TTG AAG GAC TAT GAC 720  
 Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
 225 230 235 240

TAC ACC TGC TTT GTG TTT AGT GAC GTG GAC CTC ATT CCA ATG AAT GAC 768  
 Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
 245 250 255

CAT AAT GCG TAC AGG TGT TTT TCA CAG CCA CGG CAC ATT TCC GTT GCA 816  
 His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
 260 265 270

ATG GAT AAG TTT GGA TTC AGC CTA CCT TAT GTT CAG TAT TTT GGA GGT 864  
 Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
 275 280 285

GTC TCT GCT CTA AGT AAA CAA CAG TTT CTA ACC ATC AAT GGA TTT CCT 912  
 Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
 290 295 300

AAT AAT TAT TGG GGC TGG GGA GGA GAA GAT GAT GAC ATT TTT AAC AGA 960  
 Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
 305 310 315 320

TTA GTT TTT AGA GGC ATG TCT ATA TCT CGC CCA AAT GCT GTG GTC GGG 1008  
 Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
 325 330 335

AGG TGT CGC ATG ATC CGC CAC TCA AGA GAC AAG AAA AAT GAA CCC AAT 1056  
 Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
 340 345 350

- 44 -

CCT CAG AGG TTT GAC CGA ATT GCA CAC ACA AAG GAG ACA ATG CTC TCT 1104

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser

355

360

365

GAT GGT TTG AAC TCA CTC ACC TAC CAG GTG CTG GAT GTA CAG AGA TAC 1152

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr

370

375

380

CCA TTG TAT ACC CAA ATC ACA GTG GAC ATC GGG ACA CGA GCT GGG ATC 1200

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Gly Ile

385

390

395

400

CGT CGA CCT GCA GAA TTC CAG GTG TTA AAG AGT CTG GGG AAA TTG GCC 1248

Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala

405

410

415

ATG GGG TCT GAT TCC CAG TCT GTA TCC TCA AGC AGC ACC CAG GAC CCC 1296

Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Ser Thr Gln Asp Pro

420

425

430

CAC AGG GGC CGC CAG ACC CTC GGC AGT CTC AGA GGC CTA GCC AAG GCC 1344

His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala

435

440

445

AAA CCA GAG GCC TCC TTC CAG GTG TGG AAC AAG GAC AGC TCT TCC AAA 1392

Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys

450

455

460

AAC CTT ATC CCT AGG CTG CAA AAG ATC TGG AAG AAT TAC CTA AGC ATG 1440

Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met

465

470

475

480

AAC AAG TAC AAA GTG TCC TAC AAG GGG CCA GGA CCA GGC ATC AAG TTC 1488

Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe

485

490

495

- 45 -

AGT GCA GAG GCC CTG CGC TGC CAC CTC CGG GAC CAT GTG AAT GTA TCC 1536  
 Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
                   500                                  505                                  510

ATG GTA GAG GTC ACA GAT TTT CCC TTC AAT ACC TCT GAA TGG GAG GGT 1584  
 Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
                   515                                  520                                  525

TAT CTG CCC AAG GAG AGC ATT AGG ACC AAG GCT GGG CCT TGG GGC AGG 1632  
 Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
                   530                                  535                                  540

TGT GCT GTT GTG TCG TCA GCG GGA TCT CTG AAG TCC TCC CAA CTA GGC 1680  
 Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
                   545                                  550                                  555                                  560

AGA GAA ATC GAT GAT CAT GAC GCA GTC CTG AGG TTT AAT GGG GCA CCC 1728  
 Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
                                   565                                  570                                  575

ACA GCC AAC TTC CAA CAA GAT GTG GGC ACA AAA ACT ACC ATT CGC CTG 1776  
 Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
                                   580                                  585                                  590

ATG AAC TCT CAG TTG GTT ACC ACA GAG AAG CGC TTC CTC AAA GAC AGT 1824  
 Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
                   595                                  600                                  605

TTG TAC AAT GAA GGA ATC CTA ATT GTA TGG GAC CCA TCT GTA TAC CAC 1872  
 Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
                   610                                  615                                  620

TCA GAT ATC CCA AAG TGG TAC CAG AAT CCG GAT TAT AAT TTC TTAAAC 1920  
 Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
                   625                                  630                                  635                                  640

- 46 -

AAC TAC AAG ACT TAT CGT AAG CTG CAC CCC AAT CAG CCC TTT TAC ATC 1968  
 Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
 645 650 655

CTC AAG CCC CAG ATG CCT TGG GAG CTA TGG GAC ATT CTT CAA GAA ATC 2016  
 Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
 660 665 670

TCC CCA GAA GAG ATT CAG CCA AAC CCC CCA TCC TCT GGG ATG CTT GGT 2064  
 Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
 675 680 685

ATC ATC ATC ATG ATG ACG CTG TGT GAC CAG GTG GAT ATT TAT GAG TTC 2112  
 Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
 690 695 700

CTC CCA TCC AAG CGC AAG ACT GAC GTG TGC TAC TAC TAC CAG AAG TTC 2160  
 Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
 705 710 715 720

TTC GAT AGT GCC TGC ACG ATG GGT GCC TAC CAC CCG CTG CTC TAT GAG 2208  
 Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
 725 730 735

AAG AAT TTG GTG AAG CAT CTC AAC CAG GGC ACA GAT GAG GAC ATC TAC 2256  
 Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
 740 745 750

CTG CTT GGA AAA GCC ACA CTG CCT GGC TTC CGG ACC ATT CAC TGC 2301  
 Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
 755 760 765

TAA 2304



- 47 -

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 767 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met	Arg	Leu	Arg	Glu	Pro	Leu	Leu	Ser	Gly	Ser	Ala	Ala	Met	Pro	Gly	1	5	10	15
Ala	Ser	Leu	Gln	Arg	Ala	Cys	Arg	Leu	Leu	Val	Ala	Val	Cys	Ala	Leu	20	25	30	
His	Leu	Gly	Val	Thr	Leu	Val	Tyr	Tyr	Leu	Ala	Gly	Arg	Asp	Leu	Ser	35	40	45	
Arg	Leu	Pro	Gln	Leu	Val	Gly	Val	Ser	Thr	Pro	Leu	Gln	Gly	Gly	Ser	50	55	60	
Asn	Ser	Ala	Ala	Ala	Ile	Gly	Gln	Ser	Ser	Gly	Glu	Leu	Arg	Thr	Gly	65	70	75	80
Gly	Ala	Arg	Pro	Pro	Pro	Pro	Leu	Gly	Ala	Ser	Ser	Gln	Pro	Arg	Pro	85	90	95	
Gly	Gly	Asp	Ser	Ser	Pro	Val	Val	Asp	Ser	Gly	Pro	Gly	Pro	Ala	Ser	100	105	110	
Asn	Leu	Thr	Ser	Val	Pro	Val	Pro	His	Thr	Thr	Ala	Leu	Ser	Leu	Pro	115	120	125	

- 48 -

Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
 130 135 140

Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
 145 150 155 160

Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
 165 170 175

Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
 180 185 190

Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
 195 200 205

Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
 210 215 220

Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
 225 230 235 240

Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
 245 250 255

His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
 260 265 270

Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
 275 280 285

Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
 290 295 300

Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
 305 310 315 320

- 49 -

Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
 325 330 335

Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
 340 345 350

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser  
 355 360 365

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr  
 370 375 380

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Gly Ile  
 385 390 395 400

Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala  
 405 410 415

Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Ser Thr Gln Asp Pro  
 420 425 430

His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala  
 435 440 445

Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys  
 450 455 460

Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met  
 465 470 475 480

Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe  
 485 490 495

Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
 500 505 510

- 50 -

Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
515 520 525

Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
530 535 540

Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
545 550 555 560

Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
565 570 575

Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
580 585 590

Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
595 600 605

Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
610 615 620

Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
625 630 635 640

Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
645 650 655

Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
660 665 670

Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
675 680 685

Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
690 695 700

- 51 -

Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
705                      710                      715                      720

Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
                    725                      730                      735

Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
                    740                      745                      750

Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
                    755                      760                      765

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2304 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

- (B) CLONE: YEPGSTb

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2301
- (D) OTHER INFORMATION: /product=  
"galactosyltransferase-sialyltransferase hybrid  
protein"

- 52 -

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATG AGG CTT CGG GAG CCG CTC CTG AGC GGC AGC GCC GCG ATG CCA GGC	48
Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly	
1 5 10 15	
GCG TCC CTA CAG CGG GCC TGC CGC CTG CTC GTG GCC GTC TGC GCT CTG	96
Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu	
20 25 30	
CAC CTT GGC GTC ACC CTC GTT TAC TAC CTG GCT GGC CGC GAC CTG AGC	144
His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser	
35 40 45	
CGC CTG CCC CAA CTG GTC GGA GTC TCC ACA CCG CTG CAG GGC GGC TCG	192
Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser	
50 55 60	
AAC AGT GCC GCC GCC ATC GGG CAG TCC TCC GGG GAG CTC CGG ACC GGA	240
Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly	
65 70 75 80	
GGG GCC CGG CCG CCG CCT CCT CTA GGC GCC TCC TCC CAG CCG CGC CCG	288
Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro	
85 90 95	
GGT GGC GAC TCC AGC CCA GTC GTG GAT TCT GGC CCT GGC CCC GCT AGC	336
Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser	
100 105 110	
AAC TTG ACC TCG GTC CCA GTG CCC CAC ACC ACC GCA CTG TCG CTG CCC	384
Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro	
115 120 125	

- 53 -

GCC TGC CCT GAG GAG TCC CCG CTG CTT GTG GGC CCC ATG CTG ATT GAG 432  
 Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
 130 135 140

TTT AAC ATG CCT GTG GAC CTG GAG CTC GTG GCA AAG CAG AAC CCA AAT 480  
 Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
 145 150 155 160

GTG AAG ATG GGC GGC CGC TAT GCC CCC AGG GAC TGC GTC TCT CCT CAC 528  
 Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
 165 170 175

AAG GTG GCC ATC ATC ATT CCA TTC CGC AAC CGG CAG GAG CAC CTC AAG 576  
 Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
 180 185 190

TAC TGG CTA TAT TAT TTG CAC CCA GTC CTG CAG CGC CAG CAG CTG GAC 624  
 Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
 195 200 205

TAT GGC ATC TAT GTT ATC AAC CAG GCG GGA GAC ACT ATA TTC AAT CGT 672  
 Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
 210 215 220

GCT AAG CTC CTC AAT GTT GGC TTT CAA GAA GCC TTG AAG GAC TAT GAC 720  
 Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
 225 230 235 240

TAC ACC TGC TTT GTG TTT AGT GAC GTG GAC CTC ATT CCA ATG AAT GAC 768  
 Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
 245 250 255

CAT AAT GCG TAC AGG TGT TTT TCA CAG CCA CGG CAC ATT TCC GTT GCA 816  
 His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
 260 265 270

- 54 -

ATG GAT AAG TTT GGA TTC AGC CTA CCT TAT GTT CAG TAT TTT GGA GGT 864  
Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly

275

280

285

GTC TCT GCT CTA AGT AAA CAA CAG TTT CTA ACC ATC AAT GGA TTT CCT 912  
Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro

290

295

300

AAT AAT TAT TGG GGC TGG GGA GGA GAA GAT GAT GAC ATT TTT AAC AGA 960  
Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg

305

310

315

320

TTA GTT TTT AGA GGC ATG TCT ATA TCT CGC CCA AAT GCT GTG GTC GGG 1008  
Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly

325

330

335

AGG TGT CGC ATG ATC CGC CAC TCA AGA GAC AAG AAA AAT GAA CCC AAT 1056  
Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn

340

345

350

CCT CAG AGG TTT GAC CGA ATT GCA CAC ACA AAG GAG ACA ATG CTC TCT 1104  
Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser

355

360

365

GAT GGT TTG AAC TCA CTC ACC TAC CAG GTG CTG GAT GTA CAG AGA TAC 1152  
Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr

370

375

380

CCA TTG TAT ACC CAA ATC ACA GTG GAC ATC GGG ACA CGA GCT AGG ATC 1200  
Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Arg Ile

385

390

395

400

CGT CGA CCT GCA GAA TTC CAG GTG TTA AAG AGT CTG GGG AAA TTG GCC 1248  
Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala

405

410

415



- 55 -

ATG GGG TCT GAT TCC CAG TCT GTA TCC TCA AGC AGC ACC CAG GAC CCC 1296  
 Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Ser Thr Gln Asp Pro  
                   420                   425                   430

CAC AGG GGC CGC CAG ACC CTC GGC AGT CTC AGA GGC CTA GCC AAG GCC 1344  
 His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala  
                   435                   440                   445

AAA CCA GAG GCC TCC TTC CAG GTG TGG AAC AAG GAC AGC TCT TCC AAA 1392  
 Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys  
                   450                   455                   460

AAC CTT ATC CCT AGG CTG CAA AAG ATC TGG AAG AAT TAC CTA AGC ATG 1440  
 Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met  
                   465                   470                   475                   480

AAC AAG TAC AAA GTG TCC TAC AAG GGG CCA GGA CCA GGC ATC AAG TTC 1488  
 Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe  
                   485                   490                   495

AGT GCA GAG GCC CTG CGC TGC CAC CTC CGG GAC CAT GTG AAT GTA TCC 1536  
 Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
                   500                   505                   510

ATG GTA GAG GTC ACA GAT TTT CCC TTC AAT ACC TCT GAA TGG GAG GGT 1584  
 Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
                   515                   520                   525

TAT CTG CCC AAG GAG AGC ATT AGG ACC AAG GCT GGG CCT TGG GGC AGG 1632  
 Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
                   530                   535                   540

TGT GCT GTT GTG TCG TCA GCG GGA TCT CTG AAG TCC TCC CAA CTA GGC 1680  
 Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
                   545                   550                   555                   560

- 56 -

AGA GAA ATC GAT GAT CAT GAC GCA GTC CTG AGG TTT AAT GGG GCA CCC 1728  
 Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro

565

570

575

ACA GCC AAC TTC CAA CAA GAT GTG GGC ACA AAA ACT ACC ATT CGC CTG 1776  
 Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu

580

585

590

ATG AAC TCT CAG TTG GTT ACC ACA GAG AAG CGC TTC CTC AAA GAC AGT 1824  
 Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser

595

600

605

TTG TAC AAT GAA GGA ATC CTA ATT GTA TGG GAC CCA TCT GTA TAC CAC 1872  
 Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His

610

615

620

TCA GAT ATC CCA AAG TGG TAC CAG AAT CCG GAT TAT AAT TTC TTT AAC 1920  
 Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn

625

630

635

640

AAC TAC AAG ACT TAT CGT AAG CTG CAC CCC AAT CAG CCC TTT TAC ATC 1968  
 Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile

645

650

655

CTC AAG CCC CAG ATG CCT TGG GAG CTA TGG GAC ATT CTT CAA GAA ATC 2016  
 Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile

660

665

670

TCC CCA GAA GAG ATT CAG CCA AAC CCC CCA TCC TCT GGG ATG CTT GGT 2064  
 Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly

675

680

685

ATC ATC ATC ATG ATG ACG CTG TGT GAC CAG GTG GAT ATT TAT GAG TTC 2112  
 Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe

690

695

700

- 57 -

CTC CCA TCC AAG CGC AAG ACT GAC GTG TGC TAC TAC TAC CAG AAG TTC 2160  
 Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
 705 710 715 720

TTC GAT AGT GCC TGC ACG ATG GGT GCC TAC CAC CCG CTG CTC TAT GAG 2208  
 Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
 725 730 735

AAG AAT TTG GTG AAG CAT CTC AAC CAG GGC ACA GAT GAG GAC ATC TAC 2256  
 Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
 740 745 750

CTG CTT GGA AAA GCC ACA CTG CCT GGC TTC CGG ACC ATT CAC TGC - 2301  
 Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
 755 760 765

TAA 2304

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 767 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly  
 1 5 10 15  
 Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu  
 20 25 30

- 58 -

His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser  
 35 40 45

Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser  
 50 55 60

Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly  
 65 70 75 80

Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro  
 85 90 95

Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser  
 100 105 110

Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro  
 115 120 125

Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
 130 135 140

Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
 145 150 155 160

Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
 165 170 175

Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
 180 185 190

Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
 195 200 205

Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
 210 215 220

- 59 -

Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
 225 230 235 240

Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
 245 250 255

His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
 260 265 270

Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
 275 280 285

Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
 290 295 300

Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
 305 310 315 320

Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
 325 330 335

Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
 340 345 350

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser  
 355 360 365

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr  
 370 375 380

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Arg Ile  
 385 390 395 400

Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala  
 405 410 415

- 60 -

Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Ser Thr Gln Asp Pro  
 420 425 430

His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala  
 435 440 445

Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys  
 450 455 460

Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met  
 465 470 475 480

Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe  
 485 490 495

Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
 500 505 510

Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
 515 520 525

Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
 530 535 540

Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
 545 550 555 560

Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
 565 570 575

Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
 580 585 590

Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
 595 600 605

- 61 -

Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
610 615 620

Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
625 630 635 640

Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
645 650 655

Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
660 665 670

Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
675 680 685

Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
690 695 700

Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
705 710 715 720

Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
725 730 735

Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
740 745 750

Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
755 760 765

- 62 -

Claims:

1. A protein having glycosyltransferase activity comprising identical or different catalytically active domains of glycosyltransferases.
2. A protein according to claim 1 which is a hybrid protein.
3. A protein according to claim 2 comprising a membrane-bound or soluble glycosyltransferase linked to a soluble glycosyltransferase.
4. A protein according to claim 2 comprising a suitable linker consisting of genetically encoded amino acids.
5. A protein according to claim 2 selected from the group consisting of the protein having the amino acid sequence depicted in SEQ ID NO. 5 and the protein having the amino acid sequence depicted in SEQ ID NO. 7.
6. A method for preparing a protein according to claim 2 comprising culturing a suitable transformed yeast strain under conditions which allow the expression of said protein.
7. A DNA molecule coding for a protein according to claim 2.
8. A hybrid vector comprising a DNA molecule according to claim 7.
9. A transformed yeast strain comprising a hybrid vector according to claim 8.
10. Use of a protein according to claim 1 for glycosylation.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/03194

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C12N15/54 C12N15/62 C12N15/10 C12N15/63 C12N9/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY vol. 23, no. 7/8, 1991 pages 695 - 702 SUNIL K. CAHTTERJEE 'Molecular cloning of human beta 1,4-galactosyltransferase and expression of the catalytic activity of the fusion protein in Escherichia coli' see page 695, right column, paragraph 2 see page 697, right column, paragraph 1 - page 698, right column, paragraph 4 --- -/--</p>	1,2,6,7

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

5 April 1994

Date of mailing of the international search report

04. 05. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 93/03194

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO,A,91 06635 (REGENTS OF THE UNIVERSITY OF CALIFORNIA) 16 May 1991 cited in the application see page 2, paragraph 3 - page 3, paragraph 3 see page 8, paragraph 2 see page 11, paragraph 2 - page 12, paragraph 1 see page 13, paragraph 3 see page 15, paragraph 3 - page 16, paragraph 1</p> <p>-----</p>	1,6-10

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/03194

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9106635	16-05-91	US-A- 5032519	16-07-91
		AU-B- 646233	17-02-94
		AU-A- 6648090	31-05-91
		EP-A- 0497878	12-08-92
		JP-T- 5504678	22-07-93
<hr/>			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**